1. Introduction {#s0005}
===============

Bisphosphonates remain in the skeletal bone even after their discontinuation because of their high affinity to skeletal bone ([@bb0075]). However, the clinical benefit of other anti-osteoporosis agents, except bisphosphonates, diminishes over time following discontinuation. Discontinuation of denosumab has been known to be associated with the increase of bone turnover markers to above-baseline levels (rebound in bone turnover) and rapid bone loss ([@bb0025]; [@bb0100]), and recent reports have demonstrated vertebral fractures (VFs), particularly multiple spontaneous clinical VFs (MSCVFs), occurring after discontinuation of denosumab ([@bb0010]; [@bb0110]; [@bb0050]). There is currently no recommendation for the management of VFs including MSCVFs ([@bb0050]). A bone anabolic agent such as teriparatide seems to be an effective treatment choice to treat VFs occurring after discontinuation of denosumab. However, switching therapy from denosumab to teriparatide results in transient bone loss in the spine and hip with the rebound in the bone turnover ([@bb0060]).

Sclerostin is an antagonist for canonical Wnt/β-catenin signaling that regulates bone mass, and it is a therapeutic target for the treatment of osteoporosis ([@bb0035]). Romosozumab, which became available in March 2019, is a monoclonal anti-sclerostin antibody that rapidly increases bone mass through the following dual effects on the bone: increasing bone formation and decreasing bone resorption ([@bb0095]; [@bb0070]). In a randomized controlled trial that compared romosozumab with placebo, treatment with romosozumab for 12 months showed a dramatic increase in bone mass and significant reduction of the risk of new VFs and clinical fractures among postmenopausal women with osteoporosis ([@bb0030]). Furthermore, treatment with romosozumab is reported to significantly increase bone mass among women with postmenopausal osteoporosis transitioning from alendronate treatment ([@bb0055]). The second course of romosozumab transitioning from treatment with denosumab increased bone mass in the spine, maintained bone mass in the hip, and was well tolerated ([@bb0040]). Presently, romosozumab is the strongest anti-osteoporotic agent that rapidly increases bone mass when compared with other agents, but it is uncertain that romosozumab is an effective treatment choice to treat VFs or MSCVFs occurring after discontinuation of denosumab.

To the best of our knowledge, this is the first reported case of a 60-year-old woman who was treated with romosozumab after discontinuation of denosumab and subsequently suffered MSCVFs under romosozumab treatment.

2. Case presentation {#s0010}
====================

This 60-year-old woman was firstly diagnosed with osteoporosis at the age of 57. She had a history of two VFs in the thoracic spine (T6 and T8) after lifting a heavy load. She had no other comorbidities such as cardiovascular diseases, osteomalacia, hyperthyroidism, and hyperparathyroidism. She also took no medicines which induce medication-related osteoporosis. During her first hospital visit, dual-energy absorptiometry (DXA) revealed severe osteoporosis with low bone mineral density (BMD) in the lumbar spine (T-score of −4.4) and low BMD in the femoral neck (T-score of −2.7) ([Fig. 1](#f0005){ref-type="fig"}). Initially, we strongly recommended the usage of teriparatide to increase the lumbar spine BMD, but she felt uncomfortable with self-injection. As a result, 60 mg denosumab was subcutaneously administered every 6 months, which prevented further fractures. After five denosumab injections, her lumbar spine BMD increased by 26%; however, no increase was observed within the past year ([Fig. 1](#f0005){ref-type="fig"}). Before the sixth denosumab injection in April 2019, she became sick and could not visit our hospital. Unfortunately, denosumab treatment was discontinued although we instructed her not to miss her routine visit every 6 months. The switching therapy from denosumab to romosozumab is not a standard treatment, but romosozumab was recommended in order to improve the persistent low bone mass in lumbar spine BMD. There was a 9 month-interval between the last denosumab administration and the first romosozumab administration; 210 mg Romosozumab was administered monthly since July 2019 ([Fig. 1](#f0005){ref-type="fig"}). At the first romosozumab injection, she had no clinical symptoms such as low back pain, but she experienced spontaneous severe low back pain after three doses of romosozumab. Spine radiographs did not show any vertebral deformities just after she complained severe back pain ([Fig. 2](#f0010){ref-type="fig"}B). Due to claustrophobia, earlier diagnosis using magnetic resonance images could not be performed; however, time-course radiographs revealed five new VFs (at the T12, L2, L3, L4, and L5) ([Fig. 2](#f0010){ref-type="fig"}C). Spine radiographs revealed MSCVFs and denosumab treatment was resumed after discontinuation of romosozumab.Fig. 1Treatment progress of switching from denosumab to romosozumab with changes of bone turnover markers and bone mineral density (BMD) in the lumbar spine and hip.*FN* femoral neck, *LS* lumbar spine, *P1NP* intact N-terminal propeptide of type I procollagen, *TH* total hip, *TRACP-5b* tartrate-resistant acid phosphatase 5b.Fig. 1Fig. 2Lateral spine radiographs with the patient standing. (A) Before romosozumab treatment, (B) 2 months after romosozumab treatment, (C) 4 months after romosozumab treatment. Time-course radiographs revealed five new vertebral fractures with vertebral deformity (T12, L2, L3, L4, and L5). Dot lines show the outline of L5 vertebral body.Fig. 2

At the first presentation, blood and urine tests were performed to rule out secondary osteoporosis and other bone diseases. Her serum alkaline phosphatase level was high (612 IU/L) due to bone healing after two thoracic VFs. The levels of serum calcium, blood urea nitrogen, creatinine, estimated glomerular filtration rate, and intact parathyroid hormone were within the normal range. Her serum intact N-terminal propeptide of type I procollagen (P1NP) (standard range, 26.4--98.2 μg/L) was high (111 μg/L) due to bone healing after two thoracic VFs. The tartrate-resistant acid phosphatase 5b (TRACP-5b) (standard range, 120--420 mU/dL) level was also high (863 mU/dL) ([Fig. 1](#f0005){ref-type="fig"}). During the treatment with denosumab, serum P1NP and TRACP-5b levels were lower, suggesting that denosumab efficiently suppresses bone turnover. However, discontinuation of denosumab for 3 months induced the rebound in bone turnover with the rapid increase of serum P1NP and TRACP-5b levels (P1NP, 35.7 μg/L and TRACP-5b, 370 mU/dL). At the second romosozumab injection, the serum TRACP-5b level did not decrease (before the first injection, 370 mU/dL; before the second injection, 393 mU/dL). After six doses of romosozumab, DXA revealed no increased lumbar spine BMD when compared with that obtained during the first initiation of romosozumab administration ([Fig. 1](#f0005){ref-type="fig"}). Serum P1NP and TRACP-5b levels were noted to be even higher (P1NP, 95.7 μg/L and TRACP-5b, 769 mU/dL) at 6 months after the treatment with romosozumab ([Fig. 1](#f0005){ref-type="fig"}).

3. Discussion {#s0015}
=============

Discontinuation of denosumab is associated with the rebound in bone turnover and rapid bone loss ([@bb0025]; [@bb0100]). The incidence of VFs after denosumab discontinuation is uncertain; however, MSCVFs frequently occur (≥1/100 and \<1/10) in patients not treated with bisphosphonate ([@bb0115]). In a recent review, 70 patients (69 women and one man; average age, 67.3 years) experienced 399 spontaneous VFs (median 5) within 7 and 20 (median 11) months after their last denosumab injection ([@bb0050]). Younger women tend to be at a higher risk of MSCVFs ([@bb0050]). Several studies have argued that bisphosphonate treatment before the denosumab administration can possibly reduce the risk of MSCVFs, and a sequential treatment with bisphosphonates after discontinuation of denosumab can also possibly reduce the risk ([@bb0115]; [@bb0110]; [@bb0050]). The present patient, who experienced five spontaneous VFs 11 months after the last denosumab injection was relatively young and had not been previously treated with bisphosphonate. These characteristics highly agree with those reported by other studies ([@bb0010]; [@bb0110]; [@bb0050]). We firmly believe that 9 months interval between the last denosumab injection and the initiation of romosozumab treatment induced the rebound in bone turnover and this patient experienced MSCVFs after discontinuation of denosumab, even under romosozumab treatment.

Presently, the management for VFs occurring after discontinuation of denosumab remains to be elucidated ([@bb0050]). The management should be started in the early stages and earlier diagnosis is necessary. Magnetic resonance imaging (MRI) has a high degree of accuracy for making a definite diagnosis of acute VF. MRI is useful tool to detect VF in the early stages ([@bb0020]). There is a possibility that repetitive MSCVFs in a patient who had previous MSCVFs after stopping denosumab ([@bb0085]; [@bb0015]). Delayed additional denosumab administration do not completely eliminate the risk of VFs or MSCVFs occurring after discontinuation of denosumab ([@bb0085]). Bone anabolic agents such as teriparatide and romosozumab appear to be one of the treatment choices. However, both teriparatide and romosozumab as a sequential therapy after the treatment with denosumab temporarily decrease bone loss in the spine and hip ([@bb0060]; [@bb0040]). A subsequent negative chain of multiple VFs was not prevented by romosozumab treatment in this patient. The activation of canonical Wnt/β-catenin signaling may decrease osteoclastogenesis both through osteoprotegerin produced by osteoblasts and through a direct effect on osteoclasts ([@bb0065]; [@bb0035]). However, the serum TRACP-5b level in this case did not decrease at the second romosozumab injection, the time before she complained low back pain. This revealed that activation of canonical Wnt/β-catenin signaling by romosozumab cannot show its suppressive effect on bone resorption during the rebound in bone turnover after discontinuation of denosumab. Serum P1NP and TRACP-5b levels were even higher at 6 months after the treatment with romosozumab. It is thought that bone healing process after MSCVFs have greatly affected the increase of serum P1NP and TRACP-5b levels.

To the best of our knowledge, this is the first case report of a patient who experienced MSCVFs under romosozumab treatment after discontinuation of denosumab immediately after the availability of romosozumab in the market. However, no cases of MSCVFs occurring after switching from denosumab to teriparatide were reported. There are two possible reasons for this difference. 1) Physicians rarely use teriparatide after denosumab except in the case of osteonecrosis of jaw or atypical femoral fracture occurred under denosumab treatment. Teriparatide was put on the market at 2002 in USA earlier than denosumab, and the DATA-switch study showed the transient bone loss of switching therapy from denosumab to teriparatide ([@bb0060]). However, up to date there were no reported cases with MSCVFs after switching from denosumab to teriparatide. 2) The difference in the pharmacological action between teriparatide and romosozumab may be associated with MSCVFs. Lamy et al. argued that microdamage accumulation in the cancellous bone brought by extremely high bone turnover induce fractures in spine, which are rich in cancellous bone ([@bb0050]). Teriparatide has been shown to accelerate fracture healing in animal studies ([@bb0080]; [@bb0105]), which has also been confirmed in humans ([@bb0045]). Anti-sclerostin antibody has also been reported to accelerate fracture healing in animal models ([@bb0090]); however, its effect on cancellous bone regeneration is weaker than that of teriparatide, which has more powerful effects on the mesenchymal stem cell differentiation in osteoblasts and adipocytokine inhibition ([@bb0005]). The difference in repair ability for microcracks may be associated with the occurrence of MSCVFs.

4. Conclusion {#s0020}
=============

This is the only a case report and it\'s difficult to draw a definitive conclusion from this case. However, the findings of this case suggested that romosozumab cannot demonstrate its strong dual effects on the bone during the rebound in bone turnover after discontinuation of denosumab. The least clinicians can do is to initiate the therapy at 6 months after the last denosumab injection when considering the switching therapy from denosumab to romosozumab.
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